Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valaciclovir for Psychosis in Schizophrenia
NCT01364792Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2011
- Primary completion
- Aug 2015
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valaciclovir in schizophrenia and psychosis, sponsored by University Medical Center Groningen. Primary endpoint: Hippocampal inflammation as measured by [11C]-PK11195 binding potential. Started Apr 2011; status: completed.
02
Drugs
valaciclovir
03
Conditions
schizophreniapsychosis
Beyond the preview
Go deeper on NCT01364792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01364792.